Sanofi: Will Try to Oust Medivation Board Unless Deal Talks Start -- Update
May 05 2016 - 2:41PM
Dow Jones News
By Anne Steele
Sanofi SA on Thursday said it sent a letter to Medivation Inc.
saying it would try to remove and replace members of the U.S.
biotech firm's board if it didn't engage in takeover talks.
The Paris-based drugmaker, which has a record of hostile
takeovers in the biotech sector, said in the letter that it has had
"extensive conversations" with Medivation's shareholders and that
it believes there is "overwhelming support" for a deal.
"If you are not prepared to engage with us, we have no choice
but to go directly to your shareholders," the company said.
Medivation on Thursday reiterated its rejection of Sanofi's
"substantially inadequate proposal."
"Sanofi's letter simply restates an inadequate proposal that the
Medivation board of directors has already determined substantially
undervalues the company, its leading oncology franchise, and
innovative late-stage pipeline," the company said in a
statement.
Sanofi last week said it was ready to approach Medivation
shareholders after the board rejected its $9.3 billion offer,
opening the way for a protracted takeover battle. Sanofi's offer of
$52.50 a share represented a 50% premium to Medivation's average
share price for the two months before takeover speculation emerged.
However, it is now below Medivation's share price, which closed
Wednesday at $59.06 in New York and added 1.5% in recent trading
Thursday.
In the letter, Sanofi said it could increase its offer if the
Medivation board engages in good faith discussions.
Medivation, a Nasdaq-listed company that focuses on
hard-to-treat cancers, markets one prostate-cancer therapy, Xtandi,
and has two other oncology assets in clinical development.
A takeover of Medivation would allow Sanofi to significantly
expand its drugs portfolio at a time when it is under pressure to
launch innovative medicines to make up for declining sales of its
blockbuster Lantus insulin.
"We remain enthusiastic about a potential combination with
Medivation. We and our advisors stand ready to meet at any time so
we can work to quickly consummate a mutually beneficial
transaction," Sanofi said in the letter.
Write to Anne Steele at Anne.Steele@wsj.com
(END) Dow Jones Newswires
May 05, 2016 14:26 ET (18:26 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024